Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LeonaBio (LONA) Capital Expenditures (2020 - 2024)

LeonaBio (LONA) reported Capital Expenditures of $28000.0 for Q2 2024, down 15.15% year-over-year from $33000.0 in Q3 2023, and up 460.0% on a QoQ basis from $5000.0 in Q1 2024.

LeonaBio (LONA) has 5 years of Capital Expenditures data on file, last reported at $28000.0 in Q2 2024.

  • Quarterly Capital Expenditures fell 15.15% year-over-year to $28000.0 in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $33000.0 (down 89.14% YoY) and the FY2024 annual result came in at $33000.0, down 89.14% from the prior year.
  • Capital Expenditures rose to $28000.0 in Q2 2024 per LONA's latest filing, from $5000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.0 million in Q4 2021 and bottomed at $1000.0 in Q4 2022.
  • The 5-year median for Capital Expenditures is $139500.0 (2021), against an average of $236928.6.
  • The widest annual swing landed in 2021, when Capital Expenditures surged 286.09%; it then tumbled 99.9% in 2022.
  • Tracing LONA's Capital Expenditures over 5 years: stood at $266000.0 in 2020, then surged by 286.09% to $1.0 million in 2021, then plunged by 99.9% to $1000.0 in 2022, then soared by 2900.0% to $30000.0 in 2023, then fell by 6.67% to $28000.0 in 2024.
  • Per Business Quant, the three latest LONA Capital Expenditures figures stand at $28000.0 (Q2 2024), $5000.0 (Q1 2024), and $30000.0 (Q3 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 21.83 Mn
10 LeonaBio 181.52 Mn 113.84 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 28,000.00
Jun 30, 2024 28,000.00
Mar 31, 2024 5,000.00
Mar 31, 2024 5,000.00
Sep 30, 2023 30,000.00
Sep 30, 2023 30,000.00
Jun 30, 2023 33,000.00
Jun 30, 2023 33,000.00
Mar 31, 2023 241,000.00
Mar 31, 2023 241,000.00
Dec 31, 2022 1,000.00
Dec 31, 2022 1,000.00
Sep 30, 2022 244,000.00
Sep 30, 2022 244,000.00
Jun 30, 2022 151,000.00
Jun 30, 2022 151,000.00
Mar 31, 2022 745,000.00
Mar 31, 2022 745,000.00
Dec 31, 2021 1.03 Mn
Dec 31, 2021 1.03 Mn
Sep 30, 2021 128,000.00
Sep 30, 2021 128,000.00
Jun 30, 2021 114,000.00
Jun 30, 2021 114,000.00
Mar 31, 2021 304,000.00
Mar 31, 2021 304,000.00
Dec 31, 2020 266,000.00
Dec 31, 2020 266,000.00